English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/12917
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma

AutorMolina Privado, Irene ; Rodríguez-Martínez, María ; Rebollo, Patricia; Campanero, Miguel R.
Palabras clavesBL
Etiology
Therapies
Toxicity
C-MYC translocation
E2F1
Cell proliferation
Fecha de publicación1-may-2009
EditorAmerican Association for Cancer Research
CitaciónCancer Research 69(9): 4052-4058 (2009)
ResumenCurrent treatments of sporadic Burkitt's lymphoma (sBL) are associated with severe toxicities. A better understanding of sBL formation would facilitate development of less toxic therapies. The etiology of sBL remains, however, largely unknown, C-MYC up-regulation being the only lesion known to occur in all sBL cases. Several studies examining the role of C-MYC in the pathogenesis of BL have concluded that C-MYC translocation is not the only critical event and that additional unidentified factors are expected to be involved in the formation of this tumor. We herein report that a gene distinct from C-MYC, E2F1, is involved in the formation of all or most sBL tumors. We found that E2F1 is highly expressed in Burkitt's lymphoma cell lines and sBL lymphoma specimens. Our data indicate that its elevated expression is not merely the consequence of the presence of more cycling cells in this tumor relative to other cell lines or to other neoplasias. In fact, we show that reduction of its expression in sBL cells inhibits tumor formation and decreases their proliferation rate. We also provide data suggesting that E2F1 collaborates with C-MYC in sBL formation. E2F1 expression down-regulation did not affect, however, the proliferation of human primary diploid fibroblasts. Because E2F1 is not needed for cell proliferation of normal cells, our results reveal E2F1 as a promising therapeutic target for sBL.
Descripción7 pages, 5 figures, 1 table.-- et al.
Versión del editorhttp://dx.doi.org/10.1158/0008-5472.CAN-08-4617
URIhttp://hdl.handle.net/10261/12917
DOI10.1158/0008-5472.CAN-08-4617
ISSN0008-5472
Aparece en las colecciones: (IIBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.